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Abstract
Background: Whether hypothyroidism is an independent risk factor for cardiovascular events is still disputed. We
aimed to assess the association between hypothyroidism and risks of cardiovascular events and mortality.
Methods: We searched PubMed and Embase from inception to 29 February 2016. Cohort studies were included
with no restriction of hypothyroid states. Priori main outcomes were ischemic heart disease (IHD), cardiac mortality,
cardiovascular mortality, and all-cause mortality.
Results: Fifty-five cohort studies involving 1,898,314 participants were identified. Patients with hypothyroidism,
compared with euthyroidism, experienced higher risks of IHD (relative risk (RR): 1.13; 95% confidence interval (CI):
1.01–1.26), myocardial infarction (MI) (RR: 1.15; 95% CI: 1.05–1.25), cardiac mortality (RR: 1.96; 95% CI: 1.38–2.80),
and all-cause mortality (RR: 1.25; 95% CI: 1.13–1.39); subclinical hypothyroidism (SCH; especially with thyrotropin
level ≥10 mIU/L) was also associated with higher risks of IHD and cardiac mortality. Moreover, cardiac patients
with hypothyroidism, compared with those with euthyroidism, experienced higher risks of cardiac mortality
(RR: 2.22; 95% CI: 1.28–3.83) and all-cause mortality (RR: 1.51; 95% CI: 1.26–1.81).
Conclusions: Hypothyroidism is a risk factor for IHD and cardiac mortality. Hypothyroidism is associated with
higher risks of cardiac mortality and all-cause mortality compared with euthyroidism in the general public or in
patients with cardiac disease.
Keywords: Hypothyroidism, Cardiovascular events, Mortality, Meta-analysis
Background
Thyroid hormones have wide effects on the body and
play an important role in homeostasis of the cardio-
vascular system [1]. Abnormal thyroid function has
health consequences for the general public. Patients with
hypothyroidism have an increased risk of cardiovascular
abnormalities, such as accelerated atherosclerosis [2].
Whether hypothyroidism (“hypothyroidism” refers to
the combination of subclinical hypothyroidism (SCH)
and overt hypothyroidism (OHypo) in this article), SCH
or OHypo, is an independent risk factor for cardiovascu-
lar events or mortality has conflicting opinions. It is also
conflicting whether adults with hypothyroidism and pre-
existing cardiovascular disease might be at particularly
high cardiovascular risk [3–5]. Although there have been
meta-analyses and even individual participant data (IPD)
meta-analyses on the subject so far [6–10], they have
been restricted to patients with SCH. Moreover, many
additional cohort studies have been published since. There-
fore, a comprehensive updated meta-analysis is warranted.
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This meta-analysis follows the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
Checklist (Additional file 1). We searched PubMed and
Embase from inception to 29 February 2016, using the
following text and key words, both as MeSH terms and
text words: hypothyroidism, subclinical hypothyroidism,
thyroid diseases, thyroid function, thyroid status, coron-
ary heart diseases, ischemic heart diseases, myocardial
infarction, coronary atherosclerosis, cardiovascular dis-
eases, death, mortality, heart failure, stroke, atrial fibrilla-
tion, arrhythmia, peripheral artery diseases. We searched
articles published in any language and screened references
from these studies to identify other relevant studies. YN
and YJC performed the literature search independently.
Differences were resolved by discussion.
Inclusion criteria
To minimize differences, studies were required (1) to
measure thyroid function and follow persons prospect-
ively; to assess ischemic heart disease (IHD), mortality or
other cardiovascular events; and to provide risk estimates
or sufficient data to calculate risk estimates associated
with hypothyroidism compared with euthyroidism; (2) to
be cohort studies published as original articles; and (3) to
be independent. For multiple publications of the same
study design, we included the estimates from the most re-
cent or informative reports.
Data collection and analysis
Data were extracted by one reviewer (YN) and inde-
pendently checked by another three reviewers (YJC, LJL,
and HJH); the data included the first author’s name,
publication year, location, female proportion, mean age,
mean follow-up years, sample size, study design, study
population, number of cardiovascular events and mortality,
risk estimates, categories and definitions of hypothyroidism,
thyroid treatment, and covariates adjusted for in the multi-
variable analyses. Primary authors were contacted by email
if the study did not provide the data needed. We used the
Newcastle-Ottawa scale to evaluate the quality of cohort
studies. In the present analyses, we regarded a study
awarded a total score of ≥6 as a high-quality study [11].
Hypothyroidism was categorized as SCH and OHypo.
Their definitions varied across studies. Generally, SCH
was defined as elevated thyroid-stimulating hormone
(TSH) levels and normal free tetraiodothyronine (FT4)
levels. OHypo was defined as elevated TSH but de-
creased FT4 levels [5]. In this analysis, hypothyroidism
refers to the combination of SCH and OHypo. The pri-
mary exposure of interest is hypothyroidism (i.e., par-
ticipants with an increased TSH level regardless of
FT4 level).
The primary outcomes were IHD, cardiac mortality,
cardiovascular mortality, and all-cause mortality as de-
fined by International Classification of Diseases-10-CM
(ICD-10-CM) diagnosis codes. For IHD (I20–I25), we
included angina pectoris, myocardial infarction (MI),
and chronic ischemic heart disease. For cardiac mortal-
ity, we included deaths caused by IHD, progressive heart
failure (HF), arrhythmia, or cardiac arrest (I20–I25; I44–
I50). For cardiovascular mortality, we included deaths
from diseases of the circulatory system (I00–I99). We
used both cardiac and cardiovascular mortality for the
following two reasons: first, both of them had been dis-
cussed in different meta-analyses previously; second,
the related data of both outcomes were available from
considerable original cohort studies. Therefore, it is ne-
cessary to analyze both of them in one meta-analysis to
achieve comprehensive comparison to the previous
meta-analyses. The secondary outcomes were stroke,
HF, MI, atrial fibrillation (AF), and total cardiovascular
events.
Statistical analyses
The available risk estimates that were extracted were
mostly hazard ratios (HRs), while those in partial studies
were rate ratios (RRs) [12–15], incidence rate ratios
(IRRs) [16, 17], or odds ratios (ORs) [18]. We used the
most comprehensively adjusted estimates in the reports.
When risk estimates and confidence intervals (CIs) were
not provided [19–21], we calculated RRs and CIs from
available data by using the Woolf method in Stata ver-
sion 12.1 software (used for all analyses) [9, 22]. Since
the absolute risk of IHD, cardiac mortality, cardiovascu-
lar mortality, all-cause mortality, stroke, HF, MI, AF, or
total cardiovascular events is low, the four measures of
association are expected to yield similar estimates of RR
[23, 24]. Consequently, we estimated the pooled RRs and
their CIs by using metan commands and random effects
models based on the variance model developed by
DerSimonian and Laird [9, 25]. We calculated the I2
statistic to assess heterogeneity among studies. The
formula is {(Q-df)/Q × 100%}, where Q is the chi-squared
statistic and df is its degrees of freedom [26]. We use
the following criteria: I2 < 50%, low heterogeneity; 50–
75%, moderate heterogeneity; >75%, high heterogeneity
[26, 27].
Several predefined subgroup analyses were intended to
explore potential sources of heterogeneity in primary
outcomes (metan command); where enough studies
(n ≥ 10) [28] were available, meta-regressions were con-
ducted (metareg command). Specifically, we intended to
conduct subgroup analyses by hypothyroid states and
by study population to clarify whether adults with
hypothyroidism and preexisting cardiovascular disease
were at particularly high cardiovascular risk. Given
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previous findings of the possible protective effect of
SCH in oldest old people [29], we intended to conduct
subgroup analyses by mean age of populations. Prede-
fined sensitivity analyses were performed to test the ro-
bustness of the results (metan command). When I2 ≥
50% (moderate or high heterogeneity), we used the
hetred command in Stata to evaluate the change in
between-study heterogeneity as one or more outlier
studies were excluded from the calculations, a method
which was developed by Patsopoulos [30]. If available,
we intended to perform additional subgroup analyses of
main outcomes by TSH levels (TSH ≥ 10.0 and TSH <
10.0 mIU/L) in SCH.
If there were at least 10 studies included in each out-
come of the meta-analysis, publication bias or small study
bias was assessed with a funnel plot by using Egger’s re-
gression asymmetry test (metabias6 command) [31, 32].
Statistical tests were two-sided and used a significance
level of P < 0.05.
Results
Search results
Of 3889 reports identified, we excluded 3775 studies
that were unrelated to our theme and 59 studies after
detailed evaluation. Fifty-five cohort studies met the
inclusion criteria. Figure 1 shows details of the study
selection.
Additional file 2: Table S1 shows the main characteris-
tics of the 55 included studies. Thirty-two studies were
population-based studies. Twenty-three studies were
convenience samples (i.e., particular patient groups), of
which 14 studies comprised cardiac patients. Nineteen
studies analyzed with all hypothyroidism, 34 with SCH,
and 8 with OHypo. Cohort studies included in each
outcome are mainly prospective and mostly from Europe
or North America. Thirty-seven of the 55 studies were
published in the last 5 years (2012–2016). Of the 55 co-
hort studies, 49 studies were awarded a total score of ≥6
(Additional file 2: Table S2).
Additional file 2: Table S3 shows detailed information
on adjustments in risk estimates of each cohort study.
Most risk estimates were adjusted for age (47 studies)
and sex (40 studies), which are well known as potential
confounders of both thyroid disease status and risk of
cardiovascular events. Forty studies (72.7%) reported an
adjusted estimate for at least one of the main cardiovas-
cular risk factors (body mass index (BMI), smoking,
cholesterol, hypertension, and diabetes). Seven studies’
risk estimates were adjusted for replacement therapy (RT).
Hypothyroidism and IHD
Thirteen studies with 615,596 individuals and 16,862
events analyzed with IHD. Twelve studies’ risk estimates
were adjusted for age, ten adjusted for sex, and more
than half adjusted for smoking, BMI, hypertension, or
diabetes, but only three adjusted for RT.
Overall, patients with hypothyroidism experienced a
higher risk of IHD compared to euthyroidism (RR: 1.13;
95% CI: 1.01–1.26), with evidence of low heterogeneity
(I2: 40.2%; P = 0.066; Fig. 2). Table 1 shows the results of
sensitivity analyses. Risk estimates changed little after
analyzing with fixed effects models, or after inclusion of
studies with ≥10,000 participants, studies without RT at
baseline, or high-quality studies. No publication bias was
found (Egger test: P = 0.65; Additional file 2: Figure S1).
A priori subgroup analyses were conducted across key
study characteristics (Table 2); higher risk of IHD associ-
ated with hypothyroidism was consistently observed in
Fig. 1 Flowchart of study selection
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some of these analyses. The estimates did not differ sig-
nificantly between population-based and convenience
samples studies. There was no significantly higher risk of
IHD events in cardiac patients with hypothyroidism.
However, this should be considered seriously for only
three studies included. The estimates also did not differ
significantly across other subgroups. In additional sub-
group analyses by TSH levels in patients with SCH com-
pared with euthyroidism, we observed a significantly
higher risk of IHD in SCH with TSH level ≥10.0 mIU/L
(RR: 1.32; 95% CI: 1.00–1.74; Additional file 2: Table S4).
Univariate meta-regressions showed that these a priori
factors did not affect the overall effects (Table 3).
Hypothyroidism and cardiac mortality
Of seven studies analyzed with cardiac mortality, there
were 1101 events among 34,922 participants. All studies
adjusted for age and sex, six adjusted for smoking, less
than half adjusted for other main cardiovascular risk fac-
tors, and only one study adjusted for RT.
Evidence synthesis for cardiac mortality showed a sta-
tistically strong association with hypothyroidism (RR:
1.96; 95% CI: 1.38–2.80; Fig. 3), with moderate heterogen-
eity (I2: 66.2%; P = 0.007). Sensitivity analysis by hetred
command in Stata found that two outlier studies might be
the source of heterogeneity [33, 34]. When the two outlier
studies were removed, there was evidence of low hetero-
geneity in the five remaining studies (I2: 37.9%; P = 0.17;
Table 1). The heterogeneity may have been due to the
smaller sample size of the outlier studies than that of the
other five studies (Fig. 3).
Subgroup analyses did not find the source of heterogen-
eity. However, we found that the risk of cardiac mortality
was also significantly higher in SCH (Table 2). Besides, we
observed that cardiac patients with hypothyroidism might
have a higher risk of cardiac mortality than cardiac patients
with euthyroidism (RR: 2.22; 95% CI: 1.28–3.83). Sensitivity
analyses with large cohorts or high-quality studies obtained
similar results. Considering only seven studies in this sec-
tion, we did not conduct meta-regression and funnel plots.
Hypothyroidism and cardiovascular mortality
Seventeen studies were included for cardiovascular mor-
tality, involving 158,017 participants and 5273 events.
Fig. 2 Relative risk (RR) of ischemic heart disease (IHD) associated with hypothyroidism compared with euthyroidism. The dotted line in forest plot
represents pooled RR value in random effects model. CI confidence interval
Ning et al. BMC Medicine  (2017) 15:21 Page 4 of 15
Table 1 Sensitivity analyses of pooled RRs of cardiovascular events and mortality




















Random effects 13 1.13 (1.01–1.26) 40.2% 0.07 7 1.96 (1.38–2.80) 66.2% 0.007 17 1.11 (0.97–1.28) 11.1% 0.32
Fixed effects 13 1.12 (1.05–1.20) - - 7 1.73 (1.45–2.08) - - 17 1.11 (0.99–1.25) - -
Analyses with
Large cohortb 3 1.11 (1.01–1.21) 0.0% 0.70 1 1.38 (1.03–1.84) - - 2 1.50 (1.05–2.14) 0.0% 0.52
No RT at baseline 7 1.11 (1.03–1.20) 0.0% 0.49 6 2.22 (1.52–3.24) 60.6% 0.03 8 1.13 (0.95–1.35) 5.6% 0.39
High-quality studiesc 11 1.13 (1.03–1.25) 31.5% 0.15 5 1.77 (1.23–2.54) 70.3% 0.009 14 1.11 (0.92–1.32) 23.7% 0.20
Analyses except
Outlier studyd 13 1.13 (1.01–1.26) 40.2% 0.07 5 1.55 (1.15–2.08) 37.9% 0.17 17 1.11 (0.97–1.28) 11.1% 0.32
Calculated RRse 12 1.12 (1.01–1.24) 38.3% 0.09 7 1.96 (1.38–2.80) 66.2% 0.007 16 1.11 (0.96–1.28) 16.3% 0.27




















Random effects 40 1.25 (1.13–1.39) 86.9% <0.001 9 1.09 (0.96–1.24) 52.3% 0.03 8 1.13 (0.98–1.30) 54.8% 0.03
Fixed effects 40 1.20 (1.16–1.23) - - 9 1.03 (0.97–1.09) - - 8 1.07 (1.00–1.14) - -
Analyses with
Large cohortb 7 1.18 (0.94–1.48) 97.0% <0.001 2 1.01 (0.86–1.19) 86.3% 0.007 2 1.03 (0.95–1.11) 0.0% 0.87
No RT at baseline 20 1.32 (1.10–1.59) 92.0% <0.001 1 0.93 (0.85–1.01) - - 4 1.02 (0.95–1.09) 0.0% 0.90
High-quality studiesc 34 1.25 (1.11–1.39) 88.6% <0.001 9 1.09 (0.96–1.24) 52.3% 0.03 6 1.17 (0.99–1.39) 66.3% 0.01
Analyses except
Outlier studyd 32 1.30 (1.22–1.39) 26.4% 0.09 8 1.12 (1.04–1.21) 0.0% 0.43 7 1.07 (0.94–1.21) 34.4% 0.16
Calculated RRse 38 1.27 (1.15–1.41) 87.1% <0.001 9 1.09 (0.96–1.24) 52.3% 0.03 8 1.13 (0.98–1.30) 54.8% 0.03




















Random effects 7 1.15 (1.05–1.25) 0.0% 0.43 4 1.02 (0.71–1.46) 70.6% 0.02 8 1.16 (0.97–1.38) 73.4% <0.001
Fixed effects 7 1.15 (1.05–1.25) - - 4 1.02 (0.85–1.21) - - 8 1.06 (1.01–1.11) - -
Analyses with
Large cohortb 2 1.12 (1.02–1.24) 0.0% 0.55 2 1.09 (0.59–2.02) 89.9% 0.002 2 1.15 (0.84–1.57) 92.2% <0.001
No RT at baseline 4 1.12 (1.02–1.23) 0.0% 0.57 1 0.80 (0.62–1.03) - - 3 1.12 (0.80–1.56) 25.2% 0.26
High-quality studiesc 7 1.15 (1.05–1.25) 0.0% 0.43 3 1.06 (0.66–1.70) 79.9% 0.007 8 1.19 (0.99–1.43) 73.5% <0.001
Analyses except
Outlier studyd 7 1.15 (1.05–1.25) 0.0% 0.43 3 0.83 (0.67–1.03) 0.0% 0.85 7 1.28 (1.16–1.40) 0.0% 0.50
Calculated RRse 6 1.14 (1.05–1.24) 0.0% 0.58 4 1.02 (0.71–1.46) 70.6% 0.02 8 1.16 (0.97–1.38) 73.4% <0.001
AF atrial fibrillation, CI confidence interval, HF heart failure, IHD ischemic heart disease, MI myocardial infarction, RR relative risk, RT replacement therapy
aP value for heterogeneity
bLarge cohort studies with >10,000 population
cHigh-quality studies with a total score of ≥6
dOutlier studies found by sensitivity analyses (hetred command); there were 2 for cardiac mortality, 8 for all-cause mortality, 1 for stroke, 1 for HF, 1 for AF, and 1
for total cardiovascular events
eThree cohort studies did not report the estimates: Aho et al. [21] (cardiovascular mortality), Bai et al. [20] (IHD, all-cause mortality, MI), Parle et al. [19]
(all-cause mortality)
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Fourteen studies adjusted for age, thirteen adjusted for
sex, more than half adjusted for cardiovascular risk fac-
tor, and only four adjusted for RT.
The summary RR of cardiovascular mortality associ-
ated with hypothyroidism was 1.11 (95% CI: 0.97–1.28;
Fig. 4), with low heterogeneity (I2: 11.1%; P = 0.324). In
sensitivity analyses, the risk estimates did not change
after analyzing with studies removing RT at baseline or
with high-quality studies. No publication bias was found
(Egger test: P = 0.92). In meta-regression and subgroup
analyses, the pooled RRs of each group or subgroup
were almost similar to the total.
Hypothyroidism and all-cause mortality
All-cause mortality occurred in at least 112,156 patients
among 1,036,389 participants from 40 studies. Thirty-five
studies adjusted for age, thirty-one adjusted for sex, most
adjusted for cardiovascular risk factors, and only five
adjusted for RT.
The pooled RR value of all-cause mortality was 1.25
(95% CI: 1.13–1.39; Fig. 5), with high heterogeneity
(I2: 86.9%; P < 0.001). In subgroup and meta-regression
analyses, we observed evidence for heterogeneity by study
population (P = 0.009). The RR for all-cause mortality in
convenience samples was significantly higher than that
in population-based studies; also, the risk of all-cause
mortality in cardiac patients with hypothyroidism was
significantly higher than that in cardiac patients with
euthyroidism (RR: 1.51; 95% CI: 1.26–1.81). We ob-
served that SCH was also associated with a higher risk
of all-cause mortality (RR: 1.32; 95% CI: 1.13–1.54).
In sensitivity analyses, the pooled RR value changed
little after inclusion of large cohorts, studies without RT
at baseline, or high-quality studies. Sensitivity analyses
by hetred command in Stata found eight outlier studies
[16, 18, 19, 29, 33, 35–37]. When they were removed, the
pooled RRs of the remaining studies were still significant
(RR: 1.30; 95% CI: 1.22–1.39; I2 = 26.4%). No publication
bias was found (Egger test: P = 0.44).
Hypothyroidism and stroke, HF, MI, AF, and total
cardiovascular events
For stroke, nine studies were included, reporting 27,196
events among 761,993 participants. All studies adjusted
Fig. 3 Relative risk (RR) of cardiac mortality associated with hypothyroidism compared with euthyroidism. The dotted line in forest plot represents
pooled RR value in random effects model. CI confidence interval
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for age, eight adjusted for sex, most adjusted for cardio-
vascular risk factors, and only one adjusted for RT. The
overall RR of stroke was 1.09 (95% CI: 0.96–1.24; Fig. 6)
with moderate heterogeneity (I2: 52.3%; P = 0.03). After
excluding one outlier study [16] with population >10,000,
RR changed slightly with no heterogeneity (I2: 0.0%;
P = 0.43).
Of eight studies analyzed with HF, there were 23,033
events among 599,876 participants. Seven studies adjusted
for age, all adjusted for sex, most adjusted for cardiovascu-
lar risk factors, and only two adjusted for RT. Evidence
synthesis for HF did not show a significant association
with hypothyroidism (RR: 1.13; 95% CI: 0.98–1.30; Fig. 6),
with moderate heterogeneity across studies (I2: 54.8%; P =
0.03). After excluding one outlier study [5], the heterogen-
eity decreased with the pooled RR still insignificant. We
performed an additional subgroup analysis of risk of HF
by mean age (Additional file 2: Table S5). The risk esti-
mates did not significantly change in each subgroup.
Seven studies involving 588,182 participants were ana-
lyzed reporting a total of 13,263 MI. Six studies adjusted
for age, four adjusted for sex, most adjusted for car-
diovascular risk factors, and none adjusted for RT.
Hypothyroidism was significantly associated with higher
risk of MI (RR: 1.15; 95% CI: 1.05–1.25; Fig. 7), with no
heterogeneity (I2: 0.0%; P = 0.43). The same results were
obtained after using fixed-effect models, inclusion of large
cohorts, studies without RT at baseline, or high-quality
studies.
For AF, four studies were included, reporting 18,259
events among 616,608 individuals. All studies adjusted
for age and sex, most adjusted for cardiovascular risk
factors, and only one adjusted for RT. The pooled RR
value of AF was 1.02 (95% CI: 0.71–1.46; Fig. 7), with
moderate heterogeneity (I2: 70.6%; P = 0.02). After ex-
cluding one outlier study [38] of HIV-infected patients
with a large population size, no heterogeneity was
found (I2: 0.0%; P = 0.85), but the RR was still not statis-
tically significant.
Eight studies involving 579,969 participants were ana-
lyzed reporting a total of 45,545 total cardiovascular
events. Six studies adjusted for age, six adjusted for sex,
Fig. 4 Relative risk (RR) of cardiovascular mortality associated with hypothyroidism compared with euthyroidism. The dotted line in forest plot
represents pooled RR value in random effects model. CI confidence interval
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most adjusted for cardiovascular risk factors, and none
adjusted for RT. The pooled RR for total cardiovascular
events was 1.16 (95% CI: 0.97–1.38; Fig. 7), with mod-
erate heterogeneity (I2: 73.4%; P < 0.001). Similar results
were observed in the sensitivity analyses.
Discussion
In this analysis of 1,898,314 participants from 55 cohort
studies, hypothyroidism is associated with higher risks of
IHD, MI, cardiac mortality, and all-cause mortality.
These associations mostly persist in sensitivity analyses,
indicating the stability of our results. In subgroup analyses,
we also observe that SCH is significantly associated
with higher risks of cardiac mortality (Table 2) and
IHD (TSH level ≥10.0 mIU/L; Additional file 2: Table S4).
Moreover, cardiac patients with hypothyroidism, compared
with those with euthyroidism, have a significantly higher
risk of cardiac mortality and all-cause mortality.
Our study is the first meta-analysis to evaluate risks of
cardiovascular events and mortality in hypothyroidism
with no restriction of hypothyroid states and study
population. In subgroup analyses, our results are gener-
ally consistent with previous meta-analyses showing
modest higher risks of IHD and cardiac mortality associ-
ated with SCH or SCH with TSH levels ≥10.0 mIU/L
[7–9, 39]. However, previous meta-analyses included lim-
ited studies, and had a wider 95% CI than ours, reflecting
less statistical power. Our separate analysis with MI still
shows a significant higher risk in hypothyroidism, which
further supports the higher risk of IHD. We observe that
cardiac patients with hypothyroidism experience a signifi-
cantly higher risk of cardiac mortality, but not IHD or MI,
than cardiac patients with euthyroidism. There may be
two reasons for this. First, small numbers of studies may
weaken the reliability of the results. Second, effects of
hypothyroidism on IHD events and MI might differ in dif-
ferent cardiac diseases, which require further prospective
studies to prove.
Previous meta-analyses show conflicting results of risk
of all-cause mortality in SCH. Some [8–10], but not all
[7, 39], meta-analyses find a higher risk of all-cause mor-
tality. Including 40 studies in all-cause mortality
Fig. 5 Relative risk (RR) of all-cause mortality associated with hypothyroidism compared with euthyroidism. *Two cohort studies by McQuade et
al. [45] and Mitchell et al. [46] did not provide the number of all-cause mortality events; we contacted the authors by email but didn’t receive a
reply. The dotted line in forest plot represents pooled RR value in random effects model. CI confidence interval
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analyses, we find that hypothyroidism is associated with
a higher risk of all-cause mortality in both the general
public and patients with cardiac disease.
However, our findings could not indicate that
hypothyroidism is an independent risk factor. RT might
be one of the important confounders, for only a small
number of cohort studies adjusted for RT (Additional
file 2: Table S3). Future prospective studies should pay
more attention to the RT information of each participant
and adjust the results for as many confounders as possible.
We find no significant association between hypothyroidism
and risks of stroke, HF, or AF. One previous IPD meta-
analysis focused on risk of stroke in SCH [40]. The au-
thors found that there was a higher risk of stroke in
SCH for people younger than 65 years, but no overall
effect of SCH on stroke could be demonstrated. The
other IPD meta-analysis found that risks of HF events
were increased with a TSH level of 10.0–19.9 mIU/L
[41]. Similarly, our meta-analyses results found no
overall effect of all hypothyroidism on stroke and HF.
However, as stroke and HF events were secondary out-
comes, we did not further conduct the subgroup analyses.
Higher risks of IHD, MI, and cardiac mortality with
hypothyroidism might be associated with the known ef-
fects of thyroid hormone on the circulatory system. Al-
tered endothelial function, increased atherosclerosis, and
altered coagulability have been reported to be associated
with hypothyroidism and may accelerate the develop-
ment of IHD [42].
A retrospective cohort study of patients from the United
Kingdom General Practitioner Research Database found
that levothyroxine therapy in SCH was associated with
fewer IHD events in younger individuals [43]. However, this
study is observational and susceptible to residual confound-
ing [44]. More research is needed to understand the effects
of treatment of SCH.
Fig. 6 Relative risk (RR) of stroke and heart failure (HF) associated with hypothyroidism compared with euthyroidism. The dotted line in forest plot
represents pooled RR value in random effects model. CI confidence interval
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Strengths and limitations
The strengths of this meta-analysis include strict inclu-
sion criteria, many more cohort studies included than
ever before, and predefined sensitivity and subgroup
analyses. There is no publication bias, which favors sta-
bility of the findings. Moreover, we do not restrict
hypothyroid states and study population, thus realizing a
full-scale assessment of the effects of hypothyroidism.
There are some limitations. Firstly, heterogeneity is
observed in some outcomes. However, we have found all
sources of heterogeneity, and sensitivity analyses confirm
the stability of our results. Secondly, the absence of IPD
might influence the accuracy of the results. Thirdly, thyroid
function testing was mostly performed at baseline, which
would weaken the accuracy of the results regarding the
possible change of thyroid function during follow-up.
Fig. 7 Relative risks of MI, AF and total cardiovascular events in hypothyroidism compared with euthyroidism. The dotted line in forest plot
represents pooled RR value in random effects model. AF atrial fibrillation; CI confidence interval; CV cardiovascular; MI myocardial infarction;
RR Relative risks
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Another limitation is the different TSH values used across
studies to define thyroid disease.
Conclusions
Our analyses suggest that hypothyroidism or SCH is a
risk factor for IHD and cardiac mortality. Moreover,
hypothyroidism is associated with higher risks of cardiac
mortality and all-cause mortality compared with euthyroid-
ism in both the general public and cardiac patients. Our
analyses offer more reliable evidence of higher risks of IHD
events and mortality in patients with hypothyroidism, and
highlight that cardiac patients with hypothyroidism should
be considered seriously for higher risk of cardiac mortality
and all-cause mortality. However, more high-quality pro-
spective cohort studies and randomized controlled trials
are needed to draw firmer conclusions.
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